The Expanding Utility of CAR T-Cell Therapy in LBCL

Dr. Caron Jacobson and Dr. Miguel Perales discuss the evolving landscape of CAR T-cell therapy for the treatment of relapsed and refractory large B-cell lymphoma. Over the past five years, CAR T-cell therapy has become a paradigm shift in the management of this disease, with most patients now receiving CAR T-cells as a second-line treatment. Dr. Perales notes that there has been a learning curve in toxicity management since the FDA approval of CAR T-cell products in 2017, leading to better patient selection and preemptive or prophylactic management of side effects.

Remarkably, real-world experience with CAR T-cell therapy in the United States has shown results comparable to those seen in clinical trials. This is in contrast to many other drug trials, where patient selection can significantly impact efficacy data. The reproducibility of CAR T-cell therapy results across different trial sizes and patient populations has been a notable feature of this treatment modality.

The discussion also touches upon the data presented at the ASH 2023 annual meeting regarding the use of lisocabtagene maraleucel (liso-cel) in large B-cell lymphoma in the real-world setting. The significance of these findings and their implications for CAR T-cell therapy will be explored further in the conversation.

Transcript summary generated by Claude AI.